Issue One: The Two Registers

The argument of this issue

Three public registers were queried on consecutive days in October 2026: the United States clinical trials registry, the Federal Register, and a measured record of what is searched for. Each was asked one narrow question about the same 77 compound names. The three answers do not describe one market.

Registered development is concentrated to the point of being almost a different industry from the catalogue it is supposed to belong to. Ten names account for 8,058 of 10,992 registered study records. The lower half of the same list accounts for 102. The federal publication record, meanwhile, is barely about compounds at all: it is about who may compound, under which section of the law, from which substances. And the names carrying the heaviest public attention are, with very few exceptions, not the names carrying development.

The convenient story is one sector on one growth curve. Read together, the three registers describe two populations and the regulatory channel that connects them. This issue makes that argument in four features, each set against a different register, each one re-runnable by a reader from the query printed beside every figure it uses.

There is no market size in this issue, no growth rate and no forecast. None of those is something this desk retrieved, and this publication does not print numbers it did not retrieve.

Colophon

This issue was compiled and written by the Peptide Quarterly editorial desk. There is no individual byline, nobody was interviewed, and no unnamed source appears anywhere in it.

Everything in it rests on four retrievals, made on 2026-10-09, 2026-10-12, 2026-10-13. The clinical trials registry was queried once per compound name across the 77-compound corpus, returning 10,992 study records in total, of which 1,245 were recruiting. The federal publication archive was queried for 6 terms and then once per document type for each of them. The US drug application register result stored against each compound record was read as the corpus holds it. A single search-volume instrument was read for the attention figures, and the other two demand instruments in the dataset were left alone, because the dataset’s own note says the three must never share a denominator.

The underlying corpus carries 77 compound records across 11 classes, 738 cited source records and 902 indexed study rows. Of the 62 names that appear in both the registry and the demand instrument, every one is joined on an exact name match; the 15 that do not match are absent rather than approximated.

What this issue does not contain: a market size, a growth rate, a forecast, a price, a projection, a named executive, a quotation, an interview, an anonymous source, a sponsored placement, or a recommendation about any compound. None of those was retrieved, and this publication prints only what it retrieved and can show the query for.

Where this issue argues, it says so in the article. Each feature keeps its argument in a chapter of its own, marked as the desk’s reading, so that the counts and the case built on them are never mixed.

On the word quarterly: this is the first issue and at the time of writing it is the only one. A title that promises four issues a year and has published one should say so rather than imply a back catalogue, so there is no archive yet and there is nothing behind this page. The recurring departments carry standing tables and move when the registries move. The next issue will exist when there is a second argument worth four features, and not on a date chosen to make the masthead true.